Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mike Ward
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.
Despite failing to meet the co-primary endpoints in a Phase III trial, Atlantic Healthcare believes alicaforsen enema could still be approved in orphan-designated pouchitis.
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V fund which will focus on European biotech and medtech opportunities.
European life sciences investment firm Medicxi shows institutional investor appetite for life sciences venture capital is still strong as it secures €400m in an over-subscribed offering.
The companies have agreed to a multi-year, multi-target research collaboration and license deal to discover and develop medicines that modulate GPCR targets across a range of diseases.